ADIPOCYTE 润色咨询

Adipocyte

出版年份:暂无数据 年文章数:454 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:0.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2022-04-14 ms8000001300213841

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向:中医学;生信;代谢病
    经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2022-08-18 cuiziwei-md

    审稿速度:1.0 | 投稿命中率:75.0
    经验分享:Received: 2022-05-15

    Accepted: 2022-07-25

    Published: 2022-08-17

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2021-12-10 121b4779m71(暂无昵称)

    审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2021-09-24 ms6000001748810454

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:4.53

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2020-11-25 14704480m20(暂无昵称)

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向:内科
    经验分享:不错不错,今年运气不错很快就中了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1211051, encodeId=77fa121105119, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:中医学;生信;代谢病<br>经验分享:生信类文章,4月2号投稿,格式问题4月5号重投,8号外审,13号拒了。速度倒是挺快……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1af6475562, createdName=ms8000001300213841, createdTime=Thu Apr 14 08:13:20 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239617, encodeId=0607123961e6a, content=审稿速度:1.0 | 投稿命中率:75.0<br>经验分享:Received: 2022-05-15<br><br>Accepted: 2022-07-25<br><br>Published: 2022-08-17, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff312657655, createdName=cuiziwei-md, createdTime=Thu Aug 18 22:46:06 CST 2022, time=2022-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078881, encodeId=f6d810e88817f, content=审稿人很好,期刊要求较高,但只要符合期刊立意也不会很难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=848b2275602, createdName=121b4779m71(暂无昵称), createdTime=Fri Dec 10 20:40:37 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054464, encodeId=8a9b10544643a, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:4.53, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ac5615815, createdName=ms6000001748810454, createdTime=Fri Sep 24 15:09:31 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902139, encodeId=a38d902139a3, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向:内科<br>经验分享:不错不错,今年运气不错很快就中了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56e45184744, createdName=14704480m20(暂无昵称), createdTime=Wed Nov 25 12:40:57 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580474, encodeId=a91e5804e4c6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:一审2个月,二审半个月接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/27/5c1c28f375e458734b074bfcd8876252.jpg, createdBy=c3fa2014320, createdName=TanTXiangS, createdTime=Tue Nov 26 00:00:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2019-11-26 TanTXiangS

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享:一审2个月,二审半个月接收

    1

    展开1条回复
共10条页码: 1/1页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分